BioPharmSignal logoBioPharmSignal

Biotech News

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics (NRIX)Nurix TherapeuticsEarnings

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes comprehensive clinical development plan in malignant hematology and enables

Related news

NRIXNurix Therapeutics2026-10-07 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

APGEApogee Therapeutics2026-08-10 11:00 EST

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

ANABAnaptysBio, Inc.2026-09-21 20:15 EST

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

View all latest news

Nurix Therapeutics

Targeted Protein Degradation Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies. Bexobrutideg Bexobrutideg is an oral BTK degrader being advanced as a potential...

Recent company news

NRIXNurix Therapeutics2026-10-07 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

Stock data

Close
22.60 USD
Market cap
1.69B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States